PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook
PerkinElmer, Inc. (NYSE: PKI) will release its third quarter 2022 financial results on November 8, 2022. The management will host a webcast at 8:00 a.m. ET to discuss the results. The company anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share to exceed prior guidance. Total revenue is expected to be near the high end of prior guidance, facing headwinds from foreign exchange. The company's revenue in 2021 was approximately $5 billion, serving customers in 190 countries.
- Anticipates organic revenue growth and adjusted EPS to exceed prior guidance.
- Total revenue expected near the high end of prior guidance.
- Larger than expected headwinds from foreign exchange.
The Company also announced that it anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share for the third quarter ended
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future adjusted earnings per share and revenue growth and other financial results. Words such as "believes," "intends," "anticipates," "plans," "expects," “estimates”, "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: the completion of quarterly closing procedures for the third quarter ended
About PerkinElmer
PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately
View source version on businesswire.com: https://www.businesswire.com/news/home/20221017005178/en/
Investor Relations:
(781) 663-5677
steve.willoughby@perkinelmer.com
Media Relations:
(781) 663-5728
chet.murray@perkinelmer.com
Source:
FAQ
When will PerkinElmer announce its Q3 2022 financial results?
What time is the PerkinElmer Q3 2022 earnings webcast?
What is the expected revenue growth for PerkinElmer in Q3 2022?